SCHEMBL2837059

SCHEMBL2837059

Cc1ccccc1S(=O)(=O)Nc1ccc(C(C(=O)NO)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 2/20 0.54
▸ HDAC1 Q13547 2/20 0.54
▸ HDAC3 O15379 1/20 0.54
▸ HDAC7 Q8WUI4 1/20 0.54
▸ HDAC2 Q92769 1/20 0.54
▸ HDAC10 Q969S8 1/20 0.54
▸ HDAC11 Q96DB2 1/20 0.54
▸ HDAC8 Q9BY41 1/20 0.54
▸ HDAC6 Q9UBN7 1/20 0.54
▸ HDAC9 Q9UKV0 1/20 0.54
▸ HDAC5 Q9UQL6 1/20 0.54
▸ IDH1 O75874 5/20 0.46
▸ SLC22A12 Q96S37 2/20 0.45
▸ TP53 P04637 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ MAPT P10636 2/20 0.45
▸ MMP2 P08253 1/20 0.43
▸ MMP13 P45452 1/20 0.43
▸ SLC1A3 P43003 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2841116 0.88 ALDH1A1 (0.57) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL2842237 0.86 HDAC4 (0.54) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL2880765 0.85 HDAC4 (0.67) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL2842555 0.85 ALDH1A1 (0.57) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL2844440 0.82 TSHR (0.63) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL2844092 0.82 HDAC4 (0.74) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL2837267 0.82 HDAC4 (0.63) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL2843751 0.81 HDAC4 (0.57) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL2844146 0.81 HDAC4 (0.59) HDAC4HDAC1HDAC3HDAC7HDAC2
SCHEMBL2840269 0.81 HDAC4 (0.64) HDAC4HDAC1HDAC3HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 — — EP claimed
EP-2139850-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-01-06 — — EP claimed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 — — US claimed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 — — WO claimed
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 — — EP disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 — — US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 HDAC4 10/4885HDAC1 1/4885HDAC3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback